WLBU2 peptide

This peptide was active at physiologic NaCl concentrations against S. aureus and mucoid and nonmucoid strains of P. aeruginosa (see the ref). It also kills three oral microorganisms (grown planktonically): S. gordonii, F. nucleatum, and P. gingivalis (Antimicrob Agents Chemother. 2007 May;51(5):1837-9). WLBU2 also reduced the bacterial burden of S. gordonii and F. nucleatum biofilms. The minimal DNA bundling concentrations of LL-37 and WLBU2 are similar to the concentrations necessary to ensure effective bacteria killing. CSA-13, a member of the ceragenin family, like natural LL37 or synthetic WLBU2 and HB71 peptides targets the bacterial wall through interactions with LPS and LTA. The ability of CSA-13 to maintain its bactericidal activity in the presence of negatively charged F-actin and DNA and the observed additive effect of CSA-13 with rhDNase I suggest that this synthetic antibiotic has potential advantages in treating chronic infection in CF airways (J Antimicrob Chemother. 2007 Sep;60(3):535-45). Animal model:mouse: For the mice given peptide post-bacterial infection, in the 1 mg/kg group, nine of nine animals died because of Pseudomonas sepsis; in the 3 mg/kg group, only one of nine succumbed to infection and in the 4 mg/kg group, all mice were protected (P < 0.0001) by the peptide (Deslouches B et al., 2007). 10/30/2010. The source of WLBU2 is De novo peptide design using only residues V, R, and W.